Zielen S, Scheurer J, Rhodius U, Schäfer V, Isenberg H, Bauscher P, Schröder S, Ahrens P, Hofmann D
Zentrum der Kinderheilkunde, Universität Frankfurt/Main.
Monatsschr Kinderheilkd. 1992 Dec;140(12):852-6.
In 1990 the Haemophilus influenzae b-Diphtheria conjugate vaccine (Hib-D) was introduced in Germany. In addition, most children under 18 months of age failed to develop protective levels of Hib antibodies in response to systemic infections.
To evaluate the protective efficacy of the Hib-D vaccine in Germany a post marketing case-control study was performed during 1.5. 1990-30.4. 1992. Surveillance for invasive Hib-infections was maintained by pediatricians of 8 hospitals in the Rhein-Main area. The antibody responses to Hib were evaluated by ELISA at the onset (days 0-3) and during remission of disease.
During the first year of the study 23 cases per 100,000 children of invasive Hib-infections were recorded. Of these children, 15 suffered from meningitis, 6 from epiglottitis and one from cellulitis and pericarditis respectively. None of these patients had been vaccinated except for one, who received two injections of Hib-D. Due to increased acceptance of the Hib-D vaccine we found a significant reduction of invasive Hib-infections (6 cases per 100,000 children) in the second year of the study. Again, of these children only one child was vaccinated. As expected, in all patients investigated the initial Hib antibody level was below 1 microgram/ml. The development of Hib specific immunity to invasive disease was clearly age dependent: 10 of 11 children below 18 months failed to produce any Hib antibodies (> 0.15 microgram/ml) in response to their infection. In contrast 8 of 10 children older than 18 months developed protective antibody levels to Hib.
The incidence of serious Hib-disease has significantly decreased in Germany since the introduction of the Hib-D vaccine. Because no other Hib vaccine was licensed in Germany our data confirm efficacy and safety of Hib-D reported previously. In addition, children, who contracted disease before 18 months of age, remain susceptible to Hib and require active immunization for protection.
1990年,b型流感嗜血杆菌-白喉结合疫苗(Hib-D)在德国投入使用。此外,大多数18个月以下的儿童在应对全身性感染时未能产生具有保护水平的Hib抗体。
为评估Hib-D疫苗在德国的保护效力,于1990年5月1日至1992年4月30日进行了一项上市后病例对照研究。莱茵-美因地区8家医院的儿科医生对侵袭性Hib感染进行监测。在疾病发作时(第0 - 3天)和疾病缓解期间,通过酶联免疫吸附测定法(ELISA)评估对Hib的抗体反应。
在研究的第一年,每10万名儿童中有23例侵袭性Hib感染病例被记录。在这些儿童中,15例患有脑膜炎,6例患有会厌炎,1例分别患有蜂窝织炎和心包炎。除了1名接受了两剂Hib-D疫苗注射的儿童外,这些患者均未接种过疫苗。由于对Hib-D疫苗的接受度增加,我们发现在研究的第二年侵袭性Hib感染显著减少(每10万名儿童中有6例)。同样,在这些儿童中只有1名儿童接种了疫苗。正如预期的那样,在所有接受调查的患者中,初始Hib抗体水平均低于1微克/毫升。针对侵袭性疾病的Hib特异性免疫的发展明显依赖于年龄:11名18个月以下的儿童中有10名在感染后未能产生任何Hib抗体(> 0.15微克/毫升)。相比之下,10名18个月以上的儿童中有8名产生了针对Hib的保护性抗体水平。
自Hib-D疫苗投入使用以来,德国严重Hib疾病的发病率显著下降。由于德国没有其他Hib疫苗获得许可,我们的数据证实了先前报道的Hib-D的有效性和安全性。此外,在18个月龄之前患病的儿童仍然易患Hib,需要进行主动免疫以获得保护。